EWTX News and Press, Edgewise Therapeutics Inc. From 02/13/24

2024-02-13 08:37:05 ET More on Candel, Edgewise, etc. Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing Krystal Biotech's Vyjuvek Impresses Early On, Bolsters Prospects Krystal Biotech added to Evercore’s Tactical Outperform list on...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne. EDG-5506 is an investigational orally administered small...

2024-01-29 13:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-19 16:55:57 ET Gainers: Vanda Pharmaceuticals  ( VNDA ) +5% . Edgewise Therapeutics ( EWTX ) +3% . Rush Enterprises ( RUSHA ) +2% . Cricut ( CRCT ) +2% . EchoStar Corporation ( SATS ) +2% . Losers: Fusion Pha...

2024-01-19 09:00:02 ET More on Edgewise Therapeutics Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing Edgewise wins FDA orphan drug status for muscle disorder therapy For further details see: Edgewise Therapeutics stock rises after it...

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share. Edgewise anticipates gross proceeds from the offering to be ap...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 10:30 am PT (1:30 pm ET), and a live webcast will be available at www.edgewisetx.com . Ahead of the presentation, the Com...

2024-01-07 22:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-28 15:00:21 ET Summary Edgewise Therapeutics, Inc. interim results from the phase 2 LYNX study, using EDG-5506 for the treatment of children ages 4 to 9 with DMD, are expected first half of 2024. Expansion opportunity exists to use EDG-5506 for the treatment of children an...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the J.P. Morgan 42 nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am PT (1:30 pm ET). The presentation will be webcast li...